Skip to search formSkip to main contentSkip to account menu

KD019

Known as: KD 019 
National Institutes of Health

Related topics

Related topics

3 relations
EXEL-7647XL647

Broader (1)

Tesevatinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Abstract 2590: KD019: Blood brain barrier penetrant HER2/neu, Src, and EGFR inhibitor
KD019 is an orally bioavailable small molecule inhibitor of molecular drivers of cancer growth and progression, including HER2… 
2015
2015
A phase 1b trial of blood-brain barrier (BBB)-penetrant tyrosine kinase inhibitor (TKI) tesevatinib in combination with trastuzumab for patients with HER2+ metastatic breast cancer (MBC).
608 Background: Patients with HER2+ breast cancer (BC) have a high incidence of brain metastases (mets). Tesevatinib (formerly… 
2014
2014
Abstract 1827: Inhibition of Src, HER2, and EGFR by the multi-kinase inhibitor KD019 overcomes trastuzumab resistance in breast cancer
KD019 (previously EXEL-7647) is an orally bioavailable spectrum selective small molecule kinase inhibitor of Src family… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)